{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T17:46:37Z","timestamp":1723398397151},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s00120-021-01443-6","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:04:23Z","timestamp":1611273863000},"page":"234-237","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Behandlung des Ta- und T1-Harnblasenkarzinoms von intermedi\u00e4rem oder hohem Risiko mittels intravesikalem Bacillus Calmette-Gu\u00e9rin oder Mitomycin\u00a0C"],"prefix":"10.1007","volume":"60","author":[{"given":"Nikolaos","family":"Pyrgidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Lackner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila","family":"Schneidewind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Sokolakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"1443_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel\u00a0RL, Miller\u00a0KD, Jemal\u00a0A (2018) Cancer statistics, 2018. Cancer J Clin 68:7\u201330","journal-title":"Cancer J Clin"},{"key":"1443_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","volume":"27","author":"KD Sievert","year":"2009","unstructured":"Sievert\u00a0KD, Amend\u00a0B, Nagele\u00a0U, Schilling\u00a0D, Bedke\u00a0J, Horstmann\u00a0M et\u00a0al (2009) Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27:295\u2013300","journal-title":"World J Urol"},{"key":"1443_CR3","volume-title":"EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS)","author":"M Babjuk","year":"2018","unstructured":"Babjuk\u00a0M, Burger\u00a0M, Comp\u00e9rat\u00a0E, Gontero\u00a0P, Mostafid\u00a0AH, Palou\u00a0J et al (2018) EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). European Association of Urology, Arnhem"},{"key":"1443_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","volume":"56","author":"BW van Rhijn","year":"2009","unstructured":"van Rhijn\u00a0BW, Burger\u00a0M, Lotan\u00a0Y, Solsona\u00a0E, Stief\u00a0CG, Sylvester\u00a0RJ et al (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56:430\u2013442","journal-title":"Eur Urol"},{"key":"1443_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A B\u00f6hle","year":"2003","unstructured":"B\u00f6hle\u00a0A, Jocham\u00a0D, Bock\u00a0PR (2003) Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a\u00a0formal meta-analysis of comparative studies on recurrence and toxicity. J\u00a0Urol 169:90\u201395","journal-title":"J Urol"},{"key":"1443_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ctrv.2009.12.005","volume":"36","author":"MD Shelley","year":"2010","unstructured":"Shelley\u00a0MD, Mason\u00a0MD, Kynaston\u00a0H (2010) Intravesical therapy for superficial bladder cancer: a\u00a0systematic review of randomized trials and meta-analyses. Cancer Treat Rev 36:195\u2013205","journal-title":"Cancer Treat Rev"},{"key":"1443_CR7","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte Informationen des Bundesinstituts f\u00fcr Arzneimittel und Medizinprodukte. https:\/\/www.bfarm.de\/SharedDocs\/Arzneimittelzulassung\/Lieferengpaesse\/DE\/2019\/info-BCG-medac-20191127.html. Zugegriffen: 29. Dez. 2020"},{"key":"1443_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","volume":"198","author":"BE Boehm","year":"2017","unstructured":"Boehm\u00a0BE, Cornell\u00a0JE, Wang\u00a0H, Mukherjee\u00a0N, Oppenheimer\u00a0JS, Svatek\u00a0RS (2017) Efficacy of Bacillus Calmette-Gu\u00e9rin strains for treatment of nonmuscle invasive bladder cancer: a\u00a0systematic review and network meta-analysis. J\u00a0Urol 198:503\u2013510","journal-title":"J Urol"},{"key":"1443_CR9","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/j.urology.2013.03.026","volume":"82","author":"D Michielsen","year":"2013","unstructured":"Michielsen\u00a0D (2013) Coomans: Intravesical chemotherapy or immunotherapy for intermediate-risk non-muscle invasive bladder cancer: does the patient mention a\u00a0different quality of life? Urology 82:S130\u20131","journal-title":"Urology"},{"key":"1443_CR10","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJ Arends","year":"2016","unstructured":"Arends\u00a0TJ et al (2016) Results of a\u00a0randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol 69:1046\u20131052","journal-title":"Eur Urol"},{"key":"1443_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","volume":"7","author":"SM Di Stasi","year":"2006","unstructured":"Di Stasi\u00a0SM et al (2006) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a\u00a0randomized controlled trial. Lancet Oncol 7:43\u201351","journal-title":"Lancet Oncol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01443-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-021-01443-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01443-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T01:46:53Z","timestamp":1613699213000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-021-01443-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["1443"],"URL":"https:\/\/doi.org\/10.1007\/s00120-021-01443-6","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"4 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0Pyrgidis, J.\u00a0Lackner, L.\u00a0Schneidewind und I.\u00a0Sokolakis geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}